Drugs / BBI-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05238207 | Mar 2022 → May 2023 | hereditary hemochromatosis | Bond Biosciences | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07371793 | May 2026 → Feb 2027 expected | hereditary hemochromatosis | Bond Biosciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBI-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07371793 ↗ |
| Route | Oral | “BBI-001: Oral administration immediately prior to a meal enriched with stable iron isotope Fe57” NCT05238207 ↗ |